🧫
Combination therapy with NP137 and carboplatin-paclitaxel
active
experiment
Created: 2026-04-10T14:41:11
By: etl-v1-backfill
Quality:
50%
✓ SciDEX
ID: exp-cbcfb113-31b5-45bb-91aa-a74aa6ef6d90
🧫 Experiment Protocol
Validationendometrial carcinomaNTN1endometrial carcinoma mouse modelproposed
Preclinical evaluation of combination therapy using NP137 with standard-of-care chemotherapy (carboplatin-paclitaxel) in an endometrial carcinoma mouse model. Given the importance of EMT in resistance to current standards of care, this experiment tested whether combining netrin-1 blockade with conventional chemotherapy could improve therapeutic outcomes. The study demonstrated that the combination of NP137 with carboplatin-paclitaxel outperformed carboplatin-paclitaxel alone, suggesting that netrin-1 blockade could overcome chemotherapy resistance mediated by EMT mechanisms.
PRIMARY OUTCOME
therapeutic efficacy comparison
EXPECTED OUTCOMES
Superior efficacy of combination therapy
SUCCESS CRITERIA
Improved tumor response with combination compared to chemotherapy alone
PROTOCOL
Combination treatment with NP137 plus carboplatin-paclitaxel versus carboplatin-paclitaxel alone
LINKED HYPOTHESES
Source: PMID 37532934 ↗
🧫 Experiment Extras
PATHWAY
Netrin-1 signaling, EMT pathway, DNA damage response
MARKET PRICE
$0.50
STATUS
proposed
▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | experiments |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.